Nantkwest / Immunitybio -> IBRX WKN: A2QQ2E ISIN: US45256X1037 Kürzel: IBRX Forum: Aktien User: captainpump97

Wie die Börse kurzfristig auf diese Nachrichten reagiert, kann man eigentlich nie vorhersagen. Wenn sie heute die 7,50$ Optionen killen wollen, machen sie das auch. Dennoch, alle positiven Nachrichten, werden sich auch entsprechend auszahlen, früher oder später. 😊

So verstehe ich das-> 175k Dosen sind hergestellt und bereit zur Auslieferung mit einer Haltbarkeitsdauer von 3 Jahren

https://www.urotoday.com/video-lectures/aua-2024/video/mediaitem/4037-new-bladder-cancer-treatment-mechanisms-clinical-findings-and-implications-patrick-soon-shiong.html

So verstehe ich das-> 175k Dosen sind hergestellt und bereit zur Auslieferung mit einer Haltbarkeitsdauer von 3 Jahren

Guten Morgen. Danke, fürs Teilen , sehe ich auch so, super Nachrichten. Wie muss man das mit den 175.000 Dosen verstehen? Die Nachricht gab es ja bereits. Heißt das, die sind jetzt komplett hergestellt und könnten ausgeliefert werden ?

Super Meldung an der Börse in der heutigenZeit.. Dann kann es heute ja weiter bergab gehen 😅🙈

We will present data also on Sunday on our naive study. In the naive study, the FDA, in a very unusual manner, asked us to unblind the interim analysis of the naive data that we had to date in October 2019 to confirm that the contribution of effect was Anktiva. We did so and we had 81-85%, I forget the numbers, I think it was 81% complete response by nine months. And you'll see that data on Sunday. We reached statistical difference in the duration response between BCG alone versus our combination. So it's consistent, the immunology is consistent and I'm pleased to say that the availability of this drug is so important. We recognize that. So we plan for that. By this Monday, we will release the news that we have 175,000 doses available with the stability of up to three years. 

We will present data also on Sunday on our naive study. In the naive study, the FDA, in a very unusual manner, asked us to unblind the interim analysis of the naive data that we had to date in October 2019 to confirm that the contribution of effect was Anktiva. We did so and we had 81-85%, I forget the numbers, I think it was 81% complete response by nine months. And you'll see that data on Sunday. We reached statistical difference in the duration response between BCG alone versus our combination. So it's consistent, the immunology is consistent and I'm pleased to say that the availability of this drug is so important. We recognize that. So we plan for that. By this Monday, we will release the news that we have 175,000 doses available with the stability of up to three years.